
In conjunction with


Supported by


Scientific Partner

In collaboration with


About Event
Excellence in Oncology Care 2022
The landscape for Oncology Care is changing at a rapid pace. With EIOC we envision this platform be a meeting ground for global and regional experts to meet for better learnings and take away valuable experiences to their workplace. EIOC which stands for Excellence in Oncology Care is a platform for not just one cancer specialty but a holistic approach to 14 sub therapies within Oncology.
When
21 – 23 October, 2022
Where
Intercontinental Festical City, Dubai, United Arab Emirates
- 00Days
- 00Hours
- 00Minutes
- 00Seconds

- Detailed interactive event agenda
- Personal custom agenda for specific attendees
- Attendees can save specific sessions to their personal agenda
- Live stream conference sessions, networking and interaction
- Questions can be asked live from anywhere
- Easily cycle between sessions, video, comments and Q&A

- Includes a filterable, tiered directory of sponsors/exhibitors
- Dedicated profile for each company including information, downloads, products and video
- Interact with assigned representatives immediately
- Virtual industry sponsored satellite symposia

- Instant Messaging available between onsite and offsite participants
- Ability to filter between onsite and offsite participants
- Network and set up virtual face to face meetings with other users
- Participants can connect via video call to the members of your team

- Connect with onsite and offsite participants
- Offsite participants provided with a virtual meeting automatically
- In-App live video calling
- Auto notification when the virtual meeting begins
- Make notes and download post meeting
EIOC 2021 Testimonials
2021 CME Partner

2021 Supported By








2021 Main Sponsors


2021 Platinum Sponsors



2021 Gold Sponsors




2021 Healthcare Partner

A lot of exciting data for Lung Cancer at ASCO! These are the ones I will be definitely on the look out for. https://lnkd.in/dKDf7GBc
An excellent paper that’s showing how HER2-low-positive expression showed high instability from primary BC to residual disease after neoadjuvant treatment.
https://lnkd.in/dR5h-_rE https://lnkd.in/duMevS-Z
Finally first ASCO in person after the pandemic! I am looking forward to it! Abstracts titles just released and so much to look forward to. Here is my list of Breast Abstracts that I think will be of huge interest. https://lnkd.in/dhh3tjUZ
An interesting case control study that looks at the association of cumulative lifetime excess weight with risk of Colorectal Cancer. This large-scale population-based case-control study suggest that excess weight may have substantially higher ORs associat…https://lnkd.in/dRKPNHJb
Updated 3 year survival analysis of the phase II NADIM trial is out! patients with resectable stage IIIA NSCLC received pre op chemotherapy and nivolumab. OS at 36 months was 81.9%. TMB and PDL-1 was not was predictive of survival. low pretreatment levels…https://lnkd.in/dp6PuR_p